TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33995645

Group type: EXPERIMENTAL
Intervention: Intraoperative assessment of surgical resection margin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33995988

Group type: EXPERIMENTAL
Intervention: Fostamatinib
Number of subjects: 146
Study: 33996511

Group type: EXPERIMENTAL
Intervention: Guided internet-based intervention with CBT and ACT components
Number of subjects: 52

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 52
Study: 33996579

Group type: EXPERIMENTAL
Intervention: Early Oral Feeding (EOF)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Early Nasojejunal Nutrition (ENN)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline Control
Number of subjects: 120
Study: 33996589

Group type: EXPERIMENTAL
Intervention: Pyrotinib plus vinorelbine (oral and intravenous)
Number of subjects: 97
Study: 33997376

Group type: EXPERIMENTAL
Intervention: 10g FOSS
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dextrose:FOSS (50:0 or 50:15 or 35:0 or 35:15)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: White-bread:FOSS (50:0 or 50:15 or 35:0 or 35:15)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Water alone
Number of subjects: 25
Study: 33997459

Group type: EXPERIMENTAL
Intervention: Defined menu plans with a cardioprotective diet and additional 3 g of long-chain n-3 PUFA from fish oil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nutritional counseling and incentives
Number of subjects: 60
Study: 33997734

Group type: EXPERIMENTAL
Intervention: Dream Warmer (non-electric infant warmer)
Number of subjects: 3179

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 3179
Study: 33997740

Group type: EXPERIMENTAL
Intervention: Neoadjuvant vismodegib 150 mg administered orally once daily for 4 to 10 months before planned surgery
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Neoadjuvant vismodegib
Number of subjects: 55
Study: 33997741

Group type: EXPERIMENTAL
Intervention: Fevipiprant 150 mg once daily
Number of subjects: 1347

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1347
Study: 33997942

Group type: EXPERIMENTAL
Intervention: Integration of operational strategies with new electronic technologies (e-technologies) in the Beat Acute Myeloid Leukemia Master Trial.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: e-Protocol/e-Source Upload/Electronic Data Capture Platform
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical Oversight Platform
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data Review Platform
Number of subjects: 0
Study: 33998243

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (S/V) treatment
Number of subjects: 715
Study: 33998257

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: History of migraine
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Age ≥50 years
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: History of hypertension
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Involvement of ≥3 vascular beds
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Male sex (pooled analysis)
Number of subjects: 469
Study: 33998259

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 3688

Group type: EXPERIMENTAL
Intervention: Pre-Diabetes Mellitus (pre-DM)
Number of subjects: 3688

Group type: EXPERIMENTAL
Intervention: No Diabetes Mellitus (no-DM)
Number of subjects: 3688

Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 3688
Study: 33998278

Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Number of subjects: 4774

Group type: COMPARATOR
Intervention: Control (Angiotensin-Receptor Blockers)
Number of subjects: 4774
Study: 33998279

Group type: EXPERIMENTAL
Intervention: Mean lumen diameter
Number of subjects: 4668

Group type: EXPERIMENTAL
Intervention: Mean outer wall diameter
Number of subjects: 4668

Group type: EXPERIMENTAL
Intervention: Mean wall thickness (MWT)
Number of subjects: 4668

Group type: EXPERIMENTAL
Intervention: MWT associated with age
Number of subjects: 4668

Group type: EXPERIMENTAL
Intervention: MWT associated with sex
Number of subjects: 4668

Group type: EXPERIMENTAL
Intervention: Lumen and outer wall diameters
Number of subjects: 4668

Group type: EXPERIMENTAL
Intervention: Lumen diameter decrease rate
Number of subjects: 4668
Study: 33998340

Group type: EXPERIMENTAL
Intervention: PROMIS® Anxiety Form
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalized Anxiety Disorder Scale
Number of subjects: 0
Study: 33998660

Group type: EXPERIMENTAL
Intervention: Lacosamide (200 mg to 600 mg per day)
Number of subjects: 2199
Study: 33998661

Group type: EXPERIMENTAL
Intervention: Antihelminthics (single dose during second trimester)
Number of subjects: 7873

Group type: EXPERIMENTAL
Intervention: Antihelminthics
Number of subjects: 7873
Study: 33998664

Group type: COMPARATOR
Intervention: Combination of daily calf and hamstring stretching for six weeks
Number of subjects: 201

Group type: COMPARATOR
Intervention: Calf stretching alone for 12 weeks
Number of subjects: 201

Group type: COMPARATOR
Intervention: Combination of daily calf, quadriceps, and hamstring stretching
Number of subjects: 201
Study: 33998674

Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme (ACE) inhibitors (captopril or enalapril)
Number of subjects: 635

Group type: COMPARATOR
Intervention: Alpha blockers (buflomedil or moxisylyte)
Number of subjects: 635

Group type: COMPARATOR
Intervention: Prostaglandin/prostacyclin analogues (beraprost)
Number of subjects: 635

Group type: COMPARATOR
Intervention: Thromboxane synthase inhibitors (dazoxiben)
Number of subjects: 635

Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (ketanserin)
Number of subjects: 635

Group type: COMPARATOR
Intervention: Nitrate/nitrate derivatives (nitroglycerin or glyceryl trinitrate)
Number of subjects: 635

Group type: COMPARATOR
Intervention: Phosphodiesterase inhibitors (vardenafil, cilostazol or PF-00489791)
Number of subjects: 635
Study: 33998859

Group type: EXPERIMENTAL
Intervention: High-potency cannabis
Number of subjects: 0
Study: 33998898

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33999158

Group type: EXPERIMENTAL
Intervention: Onasemnogene abeparvovec (therapeutic dose, 1.1×10^14 vg/kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Onasemnogene abeparvovec (low dose, 6.7×10^13 vg/kg)
Number of subjects: 13
Study: 33999422

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) 6.4 mg/kg Q3W
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg Q3W
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 337
Study: 33999564

Group type: EXPERIMENTAL
Intervention: Postoperative immobilization recommended by 86% (24/28) of surgeons, with 7 different methods identified. 23/24 reported full-time immobilization, most (20/23) for 4 to 6 weeks.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) for range of motion, strengthening, and return to function recommended by 96% (27/28) of surgeons, starting at a mean of 2.6 weeks postoperatively (range: 0 to 16 weeks).
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation available for 75% (21/28) of surgeons, but most (17/21) reported it was accessed by 20% or fewer of their patients.
Number of subjects: 28
Study: 33999653

Group type: EXPERIMENTAL
Intervention: Smartphone-based cervicography
Number of subjects: 164
Study: 33999698

Group type: EXPERIMENTAL
Intervention: Unifocal right-sided ablation under computed tomographic guidance
Number of subjects: 0
Study: 33999786

Group type: EXPERIMENTAL
Intervention: D/C/F/TAF 800/150/200/10 mg
Number of subjects: 109
Study: 34000061

Group type: EXPERIMENTAL
Intervention: Geriatric telemedicine assessment by a board-certified geriatrician
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard ED treatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Geriatric telemedicine assessment
Number of subjects: 50
Study: 34000072

Group type: EXPERIMENTAL
Intervention: Lactate dehydrogenase to carboxyhemoglobin ratio
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34000073

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34000076

Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Number of subjects: 513
Study: 34000211

Group type: EXPERIMENTAL
Intervention: Telehealth visits
Number of subjects: 162

Group type: COMPARATOR
Intervention: No telehealth visits
Number of subjects: 162
Study: 34000235

Group type: EXPERIMENTAL
Intervention: Cytokine adsorption during ECMO
Number of subjects: 0
Study: 34000246

Group type: EXPERIMENTAL
Intervention: Cemiplimab 350 mg intravenously every 3 weeks for up to 93 weeks
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Cemiplimab
Number of subjects: 84
Study: 34000620

Group type: EXPERIMENTAL
Intervention: 3 μg/kg/day sargramostim
Number of subjects: 5
Study: 34000747

Group type: EXPERIMENTAL
Intervention: Stand-alone Xen45 gel stent without mitomycin C (MMC)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Stand-alone Xen45 gel stent with mitomycin C (MMC)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Xen45 gel stent combined with cataract surgery without mitomycin C (MMC)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Xen45 gel stent combined with cataract surgery with mitomycin C (MMC)
Number of subjects: 177
Study: 34000994

Group type: EXPERIMENTAL
Intervention: Freeze-dried highbush blueberry powder (BBP), 50 g daily for 8 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo powder
Number of subjects: 49
Study: 34001010

Group type: EXPERIMENTAL
Intervention: Avelumab, administered in 4 doses as a short course of immunotherapy.
Number of subjects: 80
Study: 34001055

Group type: EXPERIMENTAL
Intervention: Journey of Life (JoL) intervention
Number of subjects: 600

Group type: COMPARATOR
Intervention: Waitlist-control
Number of subjects: 600
Study: 34001067

Group type: EXPERIMENTAL
Intervention: 12-month vocational rehabilitation programme
Number of subjects: 95
Study: 34001113

Group type: EXPERIMENTAL
Intervention: Self-admission to psychiatric inpatient treatment
Number of subjects: 0
Study: 34001145

Group type: EXPERIMENTAL
Intervention: Non-invasive screening for HCV antibodies (Ab) by finger prick and facilitated referral to a specialist.
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Risk factors assessment through a face-to-face questionnaire.
Number of subjects: 425
Study: 34001523

Group type: EXPERIMENTAL
Intervention: NKTR-255
Number of subjects: 0

Group type: COMPARATOR
Intervention: rhIL-15
Number of subjects: 0

Group type: COMPARATOR
Intervention: precomplexed cytokines (rhIL-15/IL-15Rα and rhIL-15 N72D/IL-15Rα Fc)
Number of subjects: 0
Study: 34001647

Group type: EXPERIMENTAL
Intervention: Canakinumab therapy
Number of subjects: 285
Study: 34001692

Group type: EXPERIMENTAL
Intervention: Dual IL-17A and IL-17F neutralization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-IL-17A therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-17F and IL-17C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-17D
Number of subjects: 0
Study: 34001709

Group type: EXPERIMENTAL
Intervention: Single-port robotic transanal minimally invasive surgery
Number of subjects: 26
Study: 34001710

Group type: EXPERIMENTAL
Intervention: Single-Port Robotic Transanal Total Mesorectal Excision
Number of subjects: 0
Study: 34001713

Group type: EXPERIMENTAL
Intervention: Contact lens-assisted crosslinking (CA-CXL) with iso-osmolar riboflavin and ultraviolet-A irradiation for 30 min (fluence, 3 mW/cm2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Contact lens-assisted crosslinking (CA-CXL)
Number of subjects: 30
Study: 34001758

Group type: EXPERIMENTAL
Intervention: Noninvasive blood pressure (NIBP) measurement at the dependent arm
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Noninvasive blood pressure (NIBP) measurement at the nondependent arm
Number of subjects: 42

Group type: COMPARATOR
Intervention: Invasive blood pressure (IBP) measurement
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: NIBP measurement at both arms
Number of subjects: 42
Study: 34001808

Group type: EXPERIMENTAL
Intervention: High-sodium dietary intervention
Number of subjects: 106

Group type: COMPARATOR
Intervention: Low-sodium dietary intervention
Number of subjects: 106
Study: 34001938

Group type: EXPERIMENTAL
Intervention: Early GDM (G1)
Number of subjects: 500
Study: 34002039

Group type: EXPERIMENTAL
Intervention: Weight fluctuations in COVID-19 survivors with overweight/obesity
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Abdominal adiposity in COVID-19 survivors with overweight/obesity
Number of subjects: 185
Study: 34002356

Group type: EXPERIMENTAL
Intervention: Daridorexant 25 mg orally
Number of subjects: 24
Study: 34002866

Group type: EXPERIMENTAL
Intervention: Pharmacological and non-pharmacological interventions
Number of subjects: 10990

Group type: COMPARATOR
Intervention: Placebo or no intervention
Number of subjects: 10990
Study: 34003074

Group type: EXPERIMENTAL
Intervention: Cisplatin, 5FU, and afatinib every 21 days followed by afatinib maintenance monotherapy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cisplatin, 5FU, and afatinib
Number of subjects: 55
Study: 34003409

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NCT)
Number of subjects: 32
Study: 34003586

Group type: EXPERIMENTAL
Intervention: Antipsychotic drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium-dependent mechanism
Number of subjects: 0
Study: 34003670

Group type: EXPERIMENTAL
Intervention: Transcatheter electrosurgical aortic leaflet laceration (BASILICA)
Number of subjects: 30
Study: 34004383

Group type: EXPERIMENTAL
Intervention: Antipsychotic discontinuation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34004576

Group type: EXPERIMENTAL
Intervention: Small molecules proposed to reverse the gene expression signature of OS based on a meta-analysis of gene expression.
Number of subjects: 93

Group type: COMPARATOR
Intervention: Validation group of 82 OS samples
Number of subjects: 93
Study: 34006024

Group type: EXPERIMENTAL
Intervention: E-health intervention with integrated and stepped psychosocial services
Number of subjects: 338

Group type: COMPARATOR
Intervention: Usual psychosocial care
Number of subjects: 338
Study: 34006027

Group type: EXPERIMENTAL
Intervention: Integrated treatment programme for eating disorders including hospitalisation, day hospital, and outpatient settings.
Number of subjects: 0
Study: 34006037

Group type: EXPERIMENTAL
Intervention: Royal Guard (dual-AI LLIN with pyriproxyfen and alpha-cypermethrin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interceptor G2 (dual-AI LLIN with chlorfenapyr and alpha-cypermethrin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olyset Plus (dual-AI LLIN with piperonyl butoxide and permethrin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interceptor LN (standard LLIN with alpha-cypermethrin)
Number of subjects: 0
Study: 34006282

Group type: EXPERIMENTAL
Intervention: Prophylactic reinforcement mesh (Group M)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Suture (Group S)
Number of subjects: 187
Study: 34006291

Group type: EXPERIMENTAL
Intervention: Matched therapy based on actionable genetic alterations (AGAs)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Matched therapy
Number of subjects: 550

Group type: COMPARATOR
Intervention: t-NGS/aCGH
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Extensive molecular profiling
Number of subjects: 550
Study: 34006315

Group type: EXPERIMENTAL
Intervention: Patients with stress-related exhaustion disorder
Number of subjects: 161

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 161
Study: 34006499

Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 mg daily, orally, in combination with durvalumab 1500 mg, intravenously, every 28 days.
Number of subjects: 16
Study: 34006504

Group type: EXPERIMENTAL
Intervention: Right Atrial Appendage (RAA) expansion index
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Left Atrial (LA) expansion index
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Right-to-left shunt (RLS) presence
Number of subjects: 60

Group type: COMPARATOR
Intervention: Right Atrial (RA) expansion index with RLS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Right Atrial Appendage (RAA) expansion index with RLS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Left Atrial (LA) expansion index with RLS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Left Atrial Appendage (LAA) expansion index with RLS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pulmonary to systemic blood flow ratio (Qp/Qs) with RLS
Number of subjects: 60
Study: 34007002

Group type: EXPERIMENTAL
Intervention: Support vector machine (svmPoly)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional PA biomarkers (plasma total 2-methylcitrate and propionylcarnitine)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Unbiased dimensional reduction using svmPoly
Number of subjects: 40
Study: 34007050

Group type: EXPERIMENTAL
Intervention: MEK inhibitor selumetinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34007150

Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept injection (IAI), 5 monthly injections followed by ProReNata regimen
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept injection (IAI)
Number of subjects: 46
Study: 34007803

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) coagulation tests (thromboelastography and Sonoclot)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Standard coagulation tests (SCTs)
Number of subjects: 142
Study: 34007845

Group type: EXPERIMENTAL
Intervention: R-HIIT
Number of subjects: 0
Study: 34007899

Group type: EXPERIMENTAL
Intervention: Nicotine patches (5-week supply mailed free-of-charge)
Number of subjects: 800
Study: 34008097

Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Partial mesorectal excision (PME)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both TME and PME
Number of subjects: 28
Study: 34008163

Group type: EXPERIMENTAL
Intervention: Dimini population
Number of subjects: 662
Study: 34008342

Group type: EXPERIMENTAL
Intervention: Escitalopram for 8 weeks followed by escitalopram monotherapy for responders or adjunctive aripiprazole for non-responders for an additional 8 weeks.
Number of subjects: 159

Group type: COMPARATOR
Intervention: Adjunctive aripiprazole for non-responders after initial treatment with escitalopram.
Number of subjects: 159
Study: 34008784

Group type: EXPERIMENTAL
Intervention: FG < p10 group
Number of subjects: 349

Group type: COMPARATOR
Intervention: Normal fasting glucose group
Number of subjects: 349
Study: 34009010

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34009072

Group type: EXPERIMENTAL
Intervention: Nutrition focused quality improvement program (QIP)
Number of subjects: 600
Study: 34009141

Group type: EXPERIMENTAL
Intervention: Bicarbonate treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Veverimer (a novel nonabsorbable polymer)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acid-lowering interventions
Number of subjects: 0
Study: 34009140

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy for uterine sarcoma in early stages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical approaches and fertility-sparing surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New targeted therapies (e.g., DNA repair machinery, immune therapies, TGF-beta pathway, mTOR inhibitors, anti-angiogenics)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care for uterine sarcoma
Number of subjects: 0
Study: 34009177

Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) imaging
Number of subjects: 2380

Group type: EXPERIMENTAL
Intervention: Ureteroscopy (URS)
Number of subjects: 2380

Group type: EXPERIMENTAL
Intervention: Endoscopic treatment
Number of subjects: 2380

Group type: EXPERIMENTAL
Intervention: Radical nephroureterectomy
Number of subjects: 2380

Group type: EXPERIMENTAL
Intervention: Segmental resection
Number of subjects: 2380

Group type: EXPERIMENTAL
Intervention: Percutaneous tumour resection
Number of subjects: 2380

Group type: EXPERIMENTAL
Intervention: Kidney sparing surgery
Number of subjects: 2380
Study: 34009243

Group type: COMPARATOR
Intervention: Resting-state functional connectivity (rsFC) in XXY males
Number of subjects: 75

Group type: COMPARATOR
Intervention: DLPFC-precuneus rsFC
Number of subjects: 75

Group type: COMPARATOR
Intervention: Functional overconnectivity
Number of subjects: 75
Study: 34009391

Group type: EXPERIMENTAL
Intervention: Complementary and Integrative Health (CIH) therapies including chiropractic, acupuncture, multimodal individualized interventions/programs, physiotherapy, and anthroposophic medicine therapy
Number of subjects: 8464
Study: 34009501

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa 1200 mg every 2 weeks until disease progression, unacceptable toxicity, or withdrawal.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa 1200 mg every 2 weeks.
Number of subjects: 30
Study: 34009837

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA) for pulmonary vein isolation (PVI)
Number of subjects: 249
Study: 34009877

Group type: EXPERIMENTAL
Intervention: Ignoring do-not-do recommendations (DNDs)
Number of subjects: 2557

Group type: EXPERIMENTAL
Intervention: Ignoring do-not-do recommendations (DNDs) in adult patients
Number of subjects: 2557

Group type: EXPERIMENTAL
Intervention: Ignoring do-not-do recommendations (DNDs) in pediatric patients
Number of subjects: 2557
Study: 34010223

Group type: EXPERIMENTAL
Intervention: Genetically elevated LDL cholesterol levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower LDL cholesterol levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statins (clinical trials)
Number of subjects: 0
Study: 34011176

Group type: EXPERIMENTAL
Intervention: Severe Food Insecurity (FI)
Number of subjects: 1247

Group type: EXPERIMENTAL
Intervention: HIV positive status
Number of subjects: 1247

Group type: COMPARATOR
Intervention: HIV negative status
Number of subjects: 1247
Study: 34011199

Group type: EXPERIMENTAL
Intervention: Telehealth-based intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34011305

Group type: EXPERIMENTAL
Intervention: Hemoglobin reference interval for children 2-36 months of age
Number of subjects: 2106

Group type: EXPERIMENTAL
Intervention: Mean Corpuscular Volume (MCV) reference interval for children 2-7 months of age
Number of subjects: 2106